Clene Posts Q2 2026 Loss, Targets Early Q4 NDA for ALS Candidate
CLNN sits 18% above its 52-week low of $3.5.
Summary
Clene reported a $13.4M net loss for Q2 2026 and announced plans to submit an NDA for its ALS drug CNM-Au8 in early Q4 2026, backed by new biomarker data.
Key Events · Earnings and Guidance · CLNN
-
NDA Submission Planned for Early Q4 2026
Clene expects to submit a New Drug Application for CNM-Au8 in ALS under the accelerated approval pathway in early fourth quarter of 2026.
-
New Biomarker Data Supports Efficacy
New analyses show CNM-Au8-treated patients whose NfL declined or stabilized lived significantly longer and performed better on functional measures than controls.
-
Cash Runway Through Late Q4 2026
Cash and equivalents of $9.7M as of June 30, 2026, expected to fund operations through late fourth quarter 2026.
-
Q2 Net Loss of $13.4M
Net loss of $13.4M, or $1.08 per share, driven by $7.5M in non-cash fair value changes in warrant and derivative liabilities.
Analysis · CLNN · Life Sciences
The second quarter brought a $13.4M net loss, but the pivotal development is the planned NDA submission for CNM-Au8 in early Q4 2026 under the accelerated approval pathway. Supporting that filing, new biomarker analyses show survival and functional benefit in patients whose NfL declined or stabilized. With cash runway extending only through late Q4 2026, the NDA filing and potential approval are critical for the company's survival.
At the time of this filing, CLNN was trading at $4.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.5M. The 52-week trading range was $3.50 to $13.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.